Macular translocation is still effective after five years

Article

It is possible for AMD patients to maintain BCVA for fives years after macular translocation surgery..

According to data published in the journal Eye it is possible for AMD patients to maintain BCVA for five years after macular translocation surgery.

A team led by Dr K. Takeuchi, Department of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Japan, assessed the medical records of 61 consecutive patients who experienced macular translocation.

Of the patients included in the study, 35 eyes were treated for AMD and 26 eyes were treated for myopic choroidal neovascularisation (mCNV). Area of the Goldmann visual field (VF) and BCVA were measured before surgery, 12 months after surgery and at the final follow-up.

In the AMD eyes the mean preoperative BCVA was 1.149±0.105 logMAR, improving to 0.69±0.06 logMAR 1 year postoperatively. The BCVA was maintained at 0.633±0.083 logMAR at the final follow-up visit.

In the mCNV eyes the mean preoperative BCVA was 1.083±0.119 logMAR, improving to 0.689±0.121 logMAR one year postoperatively. This was maintained at 0.678±0.142 logMAR at the final follow-up.

For both groups the area of the VF was significantly reduced at 12 months postoperatively and did not change significantly over the following five years.

Recent Videos
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Enrico Borrelli, MD, FEBO, speaks at EURETINA
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
© 2024 MJH Life Sciences

All rights reserved.